# A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients

> **NCT01371344** · PHASE4 · TERMINATED · sponsor: **Astellas Pharma Europe Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Heart Transplantation
- Kidney Transplantation
- Liver Transplantation

## Interventions

- **DRUG:** Tacrolimus granules
- **DRUG:** Tacrolimus capsules

## Key facts

- **NCT ID:** NCT01371344
- **Lead sponsor:** Astellas Pharma Europe Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-24
- **Primary completion:** 2017-04-02
- **Final completion:** 2017-04-02
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Trial will not complete until at least 2025 and evolution of immunosuppressant therapy has made it unlikely that patients will convert from Modigraf to Prograf.
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371344, "A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01371344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*